| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.20057 |
| P698 | PubMed publication ID | 14770441 |
| P2093 | author name string | Steven A Curley | |
| Victor G Prieto | |||
| Frederick W Holtsberg | |||
| C Mark Ensor | |||
| John S Bomalaski | |||
| Mike A Clark | |||
| Brian J Dillon | |||
| P2860 | cites work | Use of ?-asparaginase in childhood ALL | Q29041017 |
| Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells | Q36621899 | ||
| Selective growth of some rodent epithelial cells in a medium containing citrulline | Q37327617 | ||
| Arginine: biochemistry, physiology, and therapeutic implications | Q39730492 | ||
| Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. | Q40765885 | ||
| Anti‐tumor Activity of Arginine Deiminase from Mycoplasma arginini and Its Growth‐inhibitory Mechanism | Q41304088 | ||
| Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini | Q41516196 | ||
| In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini | Q41624736 | ||
| The influence of arginine upon the growth rate of a transplantable tumour in the mouse | Q42173094 | ||
| Studies of PPLO infection. V. Inhibition of lymphocyte mitosis and antibody formation by mycoplasmal extracts | Q42833969 | ||
| Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties | Q43954053 | ||
| High-level expression of Mycoplasma arginine deiminase in Escherichia coli and its efficient renaturation as an anti-tumor enzyme | Q48080000 | ||
| Depletion of Dietary Arginine Inhibits Growth of Metastatic Tumor | Q67771156 | ||
| Inhibition of growth of mammalian cell cultures by extracts of arginine-utilizing mycoplasmas | Q71355313 | ||
| Inhibition of cell division in L5178Y cells by arginine-degrading mycoplasmas: the role of arginine deiminase | Q71443383 | ||
| Mammalian cell cultures contaminated with pleuropneumonia-like organisms. I. Effect of pleuropneumonia-like organisms on growth of established cell strains | Q76484524 | ||
| INTERACTION OF MYCOPLASMA (PPLO) AND MURINE LYMPHOMA CELL CULTURES: PREVENTION OF CELL LYSIS BY ARGININE | Q76713900 | ||
| Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis | Q77998799 | ||
| Growth response of stable and primary cell cultures to L-ornithine, L-citrulline, and L-arginine | Q79293251 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 826-833 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation | |
| P478 | volume | 100 |
| Q37155873 | 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas |
| Q94470572 | A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells |
| Q36557480 | A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. |
| Q43601788 | A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. |
| Q34250146 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients |
| Q38961789 | Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. |
| Q52714391 | Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas. |
| Q30040775 | Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections |
| Q38645050 | Amino acid profiles as potential biomarkers for pediatric cancers: a preliminary communication. |
| Q35959234 | Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma |
| Q48857636 | Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers. |
| Q26765461 | Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy |
| Q35682009 | Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase |
| Q37068792 | Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis |
| Q34305783 | Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling |
| Q39822200 | Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells |
| Q37339881 | Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction |
| Q38777479 | Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug |
| Q34807813 | Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation |
| Q37160927 | Arginine deprivation as a targeted therapy for cancer |
| Q36214996 | Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. |
| Q24634269 | Arginine deprivation therapy for malignant melanoma |
| Q52889753 | Arginine starvation in colorectal carcinoma cells: Sensing, impact on translation control and cell cycle distribution. |
| Q39012828 | Arginine-Dual roles as an onconutrient and immunonutrient |
| Q35556985 | Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. |
| Q59066319 | Autophagy maintains tumour growth through circulating arginine |
| Q57781463 | Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases |
| Q39704277 | Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1. |
| Q35015474 | Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. |
| Q38813861 | Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase. |
| Q42474789 | Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. |
| Q37687381 | Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability |
| Q92323801 | Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors |
| Q84230581 | Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients |
| Q27672035 | Crystal Structures of Complexes with Cobalt-Reconstituted Human Arginase I |
| Q44095020 | Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance |
| Q41850297 | Deprivation of arginine by recombinant human arginase in prostate cancer cells |
| Q38201707 | Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. |
| Q90665359 | Dietary modifications for enhanced cancer therapy |
| Q36873800 | Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. |
| Q37306342 | Disruption of Pseudomonas putida by high pressure homogenization: a comparison of the predictive capacity of three process models for the efficient release of arginine deiminase |
| Q35233239 | Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. |
| Q35957293 | Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET. |
| Q28283880 | Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma |
| Q35021230 | Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model |
| Q38030652 | Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. |
| Q35741066 | Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency |
| Q62723432 | Homozygous SLC25A13 Mutation in a Taiwanese Patient with Adult-onset Citrullinemia Complicated with Steatosis and Hepatocellular Carcinoma |
| Q90089693 | Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy |
| Q34768395 | Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism |
| Q42153101 | L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells |
| Q50133232 | Metabolic Barriers to T Cell Function in Tumors |
| Q39265746 | Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. |
| Q38530400 | Metabolic dysregulation in monogenic disorders and cancer - finding method in madness |
| Q47759599 | Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. |
| Q92242850 | Metabolome Wide Association Study of Serum Poly and Perfluoroalkyl Substances (PFASs) in Pregnancy and Early Postpartum |
| Q49344856 | Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM. |
| Q37843621 | Microbial-based therapy of cancer: current progress and future prospects |
| Q33227163 | Molecular profiling of platinum resistant ovarian cancer. |
| Q35927116 | Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase |
| Q91826282 | New aspects of amino acid metabolism in cancer |
| Q38440838 | Novel therapeutic targets and predictive markers for hepatocellular carcinoma |
| Q37395416 | Oncogene-directed alterations in cancer cell metabolism |
| Q31139529 | Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue |
| Q38579710 | Parallel Expression of Enzyme Inhibitors of CD8T Cell Activity in Tumor Microenvironments and Secretory Endometrium |
| Q26865736 | Pathways and therapeutic targets in melanoma |
| Q34911774 | Pegylated arginine deiminase: a novel anticancer enzyme agent |
| Q38733577 | Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers |
| Q35674875 | Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors |
| Q34213639 | Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma |
| Q41457918 | Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma |
| Q38718929 | Prevention and treatment of cancers by immune modulating nutrients. |
| Q52663125 | Progress in the Management of Malignant Pleural Mesothelioma in 2017. |
| Q35170154 | Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events |
| Q34609315 | Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. |
| Q38920582 | Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: anticancer activity in vitro |
| Q39153310 | Quantitative analysis of autophagy using advanced 3D fluorescence microscopy |
| Q34832425 | RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells |
| Q37299640 | Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells |
| Q39823199 | Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. |
| Q37688620 | Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance |
| Q42323682 | Reduced expression of ASS is closely related to clinicopathological features and post-resectional survival of hepatocellular carcinoma |
| Q36277197 | Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma |
| Q53585030 | Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. |
| Q39771401 | Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. |
| Q92500806 | Role of tumor and host autophagy in cancer metabolism |
| Q36106835 | Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells |
| Q39529376 | Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation |
| Q38997841 | Synthesis and preliminary biological evaluation of O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging. |
| Q37167357 | TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation |
| Q37820202 | Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes |
| Q38792334 | Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions |
| Q26775425 | Targeting amino acid metabolism in cancer growth and anti-tumor immune response |
| Q38181070 | Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges |
| Q92573701 | Targeting extracellular nutrient dependencies of cancer cells |
| Q33838601 | The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma |
| Q93054548 | The Complex Role of Autophagy in Melanoma Evolution: New Perspectives From Mouse Models |
| Q89210695 | The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer |
| Q40188863 | The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma |
| Q49887915 | The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer |
| Q38223301 | The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials |
| Q39095939 | Three-dimensional environment renders cancer cells profoundly less susceptible to a single amino acid starvation |
| Q93053344 | mTOR signalling and cellular metabolism are mutual determinants in cancer |
Search more.